Clinical trial
Study of the Drug Efalizumab (Raptiva), for Adult Patients With Moderate to…
NCT00115076 · Rockefeller University, Other · Completed
Key facts
| NCT number | NCT00115076 |
|---|---|
| Title | Study of the Drug Efalizumab (Raptiva), for Adult Patients With Moderate to Severe Plaque Psoriasis |
| Official title | A Phase IIIB Study to Evaluate the Mechanism of Action of 1.0 mg/kg Subcutaneously Administered Efalizumab in Adults With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy |
| Lead sponsor | Rockefeller University, Other |
| Collaborators | Genentech, Inc. Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Psoriasis |
| Intervention type | Drug |
| Interventions | Efalizumab |
| Enrollment | 31 |
| Start date | Aug 4, 2003 |
| Primary completion | May 18, 2009 |
| Completion | Apr 6, 2011 |
| First posted | Jun 21, 2005 |
| Last update posted | Feb 8, 2021 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: